Zanubrutinib for treating Waldenstrom's macroglobulinaemia (WM)
Zanubrutinib is a next-generation Bruton tyrosine kinase (BTK) inhibitors that was developed to achieve BTK inhibiting efficacy while reducing the off-target adverse events documented with ibrutinib therapy
NICE state:
Reference:
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.